Markt geschlossen -
Andere Börsenplätze
|
% 5 Tage | % 1. Jan. | ||
21.06 USD | +2.38% | +1.25% | -2.55% |
Kurzporträt
Mitarbeiterzahl: 184
Manager
Manager | Titel | Alter | Seit |
---|---|---|---|
Michael Metzger
CEO | Chief Executive Officer | 53 | 05.05.15 |
Peter Ordentlich
FOU | Founder | 55 | 11.10.05 |
Neil Gallagher
PSD | President | 60 | 10.04.23 |
Keith Goldan
DFI | Director of Finance/CFO | 52 | 13.06.22 |
Chief Tech/Sci/R&D Officer | 52 | - | |
Briggs Morrison
CTO | Chief Tech/Sci/R&D Officer | 65 | 15.06.15 |
Sharon P. Klahre
IRC | Investor Relations Contact | - | 13.06.22 |
Anjali Ganguli
PRN | Corporate Officer/Principal | 48 | 01.05.15 |
Kevin McManus
HRO | Human Resources Officer | - | 01.05.23 |
Luke Albrecht
LAW | General Counsel | 45 | 01.08.16 |
Aufsichtsräte
Aufsichtsräte | Titel | Alter | Seit |
---|---|---|---|
Keith Katkin
BRD | Director/Board Member | 52 | 29.03.17 |
Dennis Podlesak
CHM | Chairman | 66 | 01.12.08 |
Pierre Legault
BRD | Director/Board Member | 63 | 04.01.17 |
William Meury
BRD | Director/Board Member | 56 | 25.09.18 |
Briggs Morrison
CTO | Chief Tech/Sci/R&D Officer | 65 | 15.06.15 |
Martin Huber
BRD | Director/Board Member | 64 | 15.09.21 |
Michael Metzger
CEO | Chief Executive Officer | 53 | 05.05.15 |
Jennifer Jarrett
BRD | Director/Board Member | 53 | 25.09.18 |
Anteilsklasse
Vote | Menge | Streubesitz | Konzerneigene Aktien | Total Float | |
---|---|---|---|---|---|
Aktie A | 1 | 84 979 686 | 83 411 029 ( 98,15 %) | 0 | 98,15 % |
Unternehmenskontakt
Syndax Pharmaceuticals, Inc.
35 Gatehouse Drive Building D
02451, Waltham
+781 419 1400
http://www.syndax.comSektor
Verlauf des Gewinns je Aktie
% 1. Jan. | Kap. | |
---|---|---|
-2.55% | 1.79 Mrd. | |
+1.51% | 42.75 Mrd. | |
+8.57% | 41.34 Mrd. | |
+49.22% | 41.61 Mrd. | |
-12.36% | 26.59 Mrd. | |
+8.92% | 25.49 Mrd. | |
-25.13% | 18.12 Mrd. | |
+29.17% | 12.24 Mrd. | |
-3.12% | 11.76 Mrd. | |
+6.35% | 11 Mrd. |
- Börse
- Aktien
- A2AFL6 Aktie
- Unternehmen Syndax Pharmaceuticals, Inc.